WO1999020256A3 - Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation - Google Patents

Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation Download PDF

Info

Publication number
WO1999020256A3
WO1999020256A3 PCT/EP1998/006429 EP9806429W WO9920256A3 WO 1999020256 A3 WO1999020256 A3 WO 1999020256A3 EP 9806429 W EP9806429 W EP 9806429W WO 9920256 A3 WO9920256 A3 WO 9920256A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicament
tissue
specific application
excipient particles
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1998/006429
Other languages
English (en)
French (fr)
Other versions
WO1999020256A2 (de
Inventor
Rainer H Mueller
Martin Lueck
Joerg Kreuter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DDS Drug Delivery Services Gesellschaft zur Foerderung der Forschung in Pharmazeutischer Technologie und Biopharmazie mbH
Original Assignee
DDS Drug Delivery Services Gesellschaft zur Foerderung der Forschung in Pharmazeutischer Technologie und Biopharmazie mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/529,600 priority Critical patent/US6288040B1/en
Priority to AT98955425T priority patent/ATE249209T1/de
Priority to JP2000516655A priority patent/JP2002521311A/ja
Priority to EP98955425A priority patent/EP1023052B1/de
Priority to CA002308236A priority patent/CA2308236A1/en
Priority to DE59809588T priority patent/DE59809588D1/de
Application filed by DDS Drug Delivery Services Gesellschaft zur Foerderung der Forschung in Pharmazeutischer Technologie und Biopharmazie mbH filed Critical DDS Drug Delivery Services Gesellschaft zur Foerderung der Forschung in Pharmazeutischer Technologie und Biopharmazie mbH
Priority to AU12272/99A priority patent/AU1227299A/en
Publication of WO1999020256A2 publication Critical patent/WO1999020256A2/de
Publication of WO1999020256A3 publication Critical patent/WO1999020256A3/de
Anticipated expiration legal-status Critical
Priority to AU2003200687A priority patent/AU2003200687A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D29/00—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor
    • B01D29/11—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor with bag, cage, hose, tube, sleeve or like filtering elements
    • B01D29/114—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor with bag, cage, hose, tube, sleeve or like filtering elements arranged for inward flow filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D29/00—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor
    • B01D29/50—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor with multiple filtering elements, characterised by their mutual disposition
    • B01D29/52—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor with multiple filtering elements, characterised by their mutual disposition in parallel connection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D29/00—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor
    • B01D29/96—Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups B01D24/00 - B01D27/00; Filtering elements therefor in which the filtering elements are moved between filtering operations; Particular measures for removing or replacing the filtering elements; Transport systems for filters
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J8/00—Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes
    • B01J8/005—Separating solid material from the gas/liquid stream
    • B01J8/006—Separating solid material from the gas/liquid stream by filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J8/00—Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes
    • B01J8/18—Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes with fluidised particles
    • B01J8/20—Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes with fluidised particles with liquid as a fluidising medium
    • B01J8/22—Chemical or physical processes in general, conducted in the presence of fluids and solid particles; Apparatus for such processes with fluidised particles with liquid as a fluidising medium gas being introduced into the liquid
    • C—CHEMISTRY; METALLURGY
    • C10—PETROLEUM, GAS OR COKE INDUSTRIES; TECHNICAL GASES CONTAINING CARBON MONOXIDE; FUELS; LUBRICANTS; PEAT
    • C10G—CRACKING HYDROCARBON OILS; PRODUCTION OF LIQUID HYDROCARBON MIXTURES, e.g. BY DESTRUCTIVE HYDROGENATION, OLIGOMERISATION, POLYMERISATION; RECOVERY OF HYDROCARBON OILS FROM OIL-SHALE, OIL-SAND, OR GASES; REFINING MIXTURES MAINLY CONSISTING OF HYDROCARBONS; REFORMING OF NAPHTHA; MINERAL WAXES
    • C10G2/00—Production of liquid hydrocarbon mixtures of undefined composition from oxides of carbon
    • C10G2/30—Production of liquid hydrocarbon mixtures of undefined composition from oxides of carbon from carbon monoxide with hydrogen
    • C10G2/32—Production of liquid hydrocarbon mixtures of undefined composition from oxides of carbon from carbon monoxide with hydrogen with the use of catalysts
    • C10G2/34—Apparatus, reactors
    • C10G2/342—Apparatus, reactors with moving solid catalysts
    • C10G2/343—Apparatus, reactors with moving solid catalysts according to the "moving-bed" method
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2201/00—Details relating to filtering apparatus
    • B01D2201/04—Supports for the filtering elements
    • B01D2201/0469—Filter tubes connected to collector tubes
    • B01D2201/0484—Filter tubes connected to collector tubes suspended from collector tubes at the upper side of the filter elements
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Combustion & Propulsion (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Die Anmeldung betrifft Arzneistoffträgerpartikel, die für die gewebespezifische Arzneistoffappplikation, speziell zum zentralen Nervensystem (ZNS), geeignet sind und in Wirkstoff-beladener oder Wirkstoff-freier Form vorliegen, wobei an die Partikeloberfläche mindestens ein Erkennungsprotein gebunden ist oder die Partikeloberfläche so modifiziert ist, daß bei Kontakt mit einem Erkennungsprotein dieses daran gebunden wird.
PCT/EP1998/006429 1997-10-17 1998-10-13 Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation Ceased WO1999020256A2 (de)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AT98955425T ATE249209T1 (de) 1997-10-17 1998-10-13 Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation
JP2000516655A JP2002521311A (ja) 1997-10-17 1998-10-13 組織特異的な薬物適用のための薬物キャリア粒子
EP98955425A EP1023052B1 (de) 1997-10-17 1998-10-13 Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation
CA002308236A CA2308236A1 (en) 1997-10-17 1998-10-13 Medicament excipient particles for tissue-specific application of a medicament
DE59809588T DE59809588D1 (de) 1997-10-17 1998-10-13 Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation
US09/529,600 US6288040B1 (en) 1997-10-17 1998-10-13 Medicament excipient particles for tissue-specific application of a medicament
AU12272/99A AU1227299A (en) 1997-10-17 1998-10-13 Medicament excipient particles for tissue-specific application of a medicament
AU2003200687A AU2003200687A1 (en) 1997-10-17 2003-02-25 Medicament excipient particles for tissue-specific application of a medicament

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19745950A DE19745950A1 (de) 1997-10-17 1997-10-17 Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
DE19745950.1 1997-10-17

Publications (2)

Publication Number Publication Date
WO1999020256A2 WO1999020256A2 (de) 1999-04-29
WO1999020256A3 true WO1999020256A3 (de) 1999-08-19

Family

ID=7845860

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1998/006429 Ceased WO1999020256A2 (de) 1997-10-17 1998-10-13 Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation

Country Status (8)

Country Link
US (1) US6288040B1 (de)
EP (2) EP1023052B1 (de)
JP (1) JP2002521311A (de)
AT (1) ATE249209T1 (de)
AU (2) AU1227299A (de)
CA (1) CA2308236A1 (de)
DE (2) DE19745950A1 (de)
WO (1) WO1999020256A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3176097A (en) 1997-06-13 1998-12-30 Medinova Medical Consulting Gmbh Drug targeting system, method of its preparation and its use
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
KR20020012215A (ko) * 1999-05-07 2002-02-15 파르마솔 게엠베하 지질 매트릭스-약물 컨쥬게이트로부터 조제된 활성성분의투여 제어를 위한 약물 운반체
CA2373239A1 (en) * 1999-05-20 2000-11-30 Pharmasol Gmbh Stability, biocompatibility optimized adjuvant (sba) for enhancing humoral and cellular immune response
EP1100475A1 (de) * 1999-06-02 2001-05-23 Medinova Medical Consulting Gmbh Verwendung von arzneistoffbeladenen nanopartikel zur behandlung von krebs
US20040126900A1 (en) * 2001-04-13 2004-07-01 Barry Stephen E High affinity peptide- containing nanoparticles
DE10121982B4 (de) * 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
DE10240035A1 (de) 2002-08-30 2004-03-11 Rehm, Bernd H.A., PD Dr.rer.nat. Biogene Polyester-Partikel definierter Größe mit funktionalisierten Oberflächen:Herstellungsverfahren und pharmazeutische Zubereitungen, in denen diese enthalten sind
CN101284136A (zh) * 2002-12-03 2008-10-15 布朗歇特洛克菲勒神经科学研究所 传输物质穿过血脑屏障的人工低密度脂蛋白载体
US7803400B2 (en) 2002-12-03 2010-09-28 Blanchette Rockefeller Neurosciences Institute Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier
EP2314285B2 (de) 2003-02-14 2019-09-18 Children's Hospital & Research Center at Oakland Träger zur freisetzung lipophilisches wirkstoffes und desen verwendungsverfahren
WO2004105799A1 (ja) * 2003-05-29 2004-12-09 Toudai Tlo, Ltd. 安定化高分子ミセル
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
DE102005007374A1 (de) * 2005-02-17 2006-08-24 Universität Ulm Nanopartikel und deren Verwendung
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US8367113B2 (en) 2006-05-15 2013-02-05 Massachusetts Institute Of Technology Polymers for functional particles
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US8821943B2 (en) * 2006-09-12 2014-09-02 Board Of Regents Of The University Of Nebraska Methods and compositions for targeted delivery of therapeutic agents
US8124598B2 (en) * 2006-09-14 2012-02-28 Sharon Sageman 7-keto DHEA for psychiatric use
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
DE102007006663A1 (de) * 2007-02-10 2008-08-21 Lts Lohmann Therapie-Systeme Ag Transport von Arzneistoffen über die Blut-Hirn-Schranke mittels Apolipoproteinen
WO2008124632A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
EP2182978A4 (de) * 2007-07-20 2012-03-21 Sanomune Inc Gewebe-kallikrein zur behandlung von erkrankungen im zusammenhang mit amyloid-protein
US20100160274A1 (en) * 2007-09-07 2010-06-24 Sharon Sageman 7-KETO DHEA for Psychiatric Use
EP2630966B1 (de) 2007-10-12 2017-04-19 Massachusetts Institute of Technology Impfstoffnanotechnologie
US9550827B2 (en) 2007-10-19 2017-01-24 The Regents Of The University Of California Methods for ameliorating and preventing central nervous system inflammation
EP2070521A1 (de) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Nanopartikel mit modifizierter Oberfläche
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
CA2762653A1 (en) 2009-05-27 2010-12-02 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
AU2011258165B2 (en) 2010-05-26 2016-11-17 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
WO2012061717A1 (en) 2010-11-05 2012-05-10 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
JP2014521687A (ja) 2011-07-29 2014-08-28 セレクタ バイオサイエンシーズ インコーポレーテッド 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (de) 2012-06-04 2017-02-22 Diamedica Inc. Kallikrein-1-glycosylierungsisoformen aus menschlichem gewebe
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
US20170000899A1 (en) * 2013-11-26 2017-01-05 The Brigham And Women's Hospital, Inc. Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
US20230143984A1 (en) * 2020-03-20 2023-05-11 Heidelberg University Colloidal carrier systems for transfer of agents to a desired site of action

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000076A1 (en) * 1991-06-24 1993-01-07 Minnesota Mining And Manufacturing Company Carrier systems for drugs
DE4310935A1 (de) * 1992-04-02 1993-11-18 Zerbini E J Fundacao Mikroemulsionen, deren Herstellung sowie Verwendung bei der Behandlung von Krebserkrankungen
WO1995000126A1 (en) * 1993-06-22 1995-01-05 Sandoz Ltd. Surface-modified albumin microspheres and pharmaceutical compositions containing them
WO1995026376A2 (en) * 1994-03-28 1995-10-05 University Of Nottingham Polymer microspheres and a method of production thereof
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0238645A1 (de) * 1985-10-03 1987-09-30 Biotechnology Research Partners, Ltd. Neue arzneimittel verabreichende systeme auf der basis von lipoproteinen
CH677886A5 (de) * 1989-06-26 1991-07-15 Hans Georg Prof Dr Weder
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
DE4018325A1 (de) * 1990-06-08 1991-12-12 Nattermann A & Cie Bestimmung der abbaurate von lipoproteinen und apoproteinen
AU652778B2 (en) * 1990-10-15 1994-09-08 Quest International B.V. Treatment composition
FR2677272B1 (fr) * 1991-06-05 1995-03-03 Biovecteurs As Vecteur particulaire a tropisme selectif, procede de preparation et composition pharmaceutique.
DE4407898A1 (de) * 1994-03-09 1995-09-14 Hoechst Ag Nanopartikel, enthaltend einen Wirkstoff und ein Polyketalweinsäureamid, Verfahren zu ihrer Herstellung und Verwendung derselben
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6313089B1 (en) * 1997-08-20 2001-11-06 Duke University Complexes of apolipoprotein E and ciliary neurotrophic factor (CNTF) and methods of use
WO1999016460A2 (en) * 1997-09-30 1999-04-08 Duke University Apolipoprotein e/growth factor complexes and methods of use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000076A1 (en) * 1991-06-24 1993-01-07 Minnesota Mining And Manufacturing Company Carrier systems for drugs
DE4310935A1 (de) * 1992-04-02 1993-11-18 Zerbini E J Fundacao Mikroemulsionen, deren Herstellung sowie Verwendung bei der Behandlung von Krebserkrankungen
WO1995000126A1 (en) * 1993-06-22 1995-01-05 Sandoz Ltd. Surface-modified albumin microspheres and pharmaceutical compositions containing them
WO1995026376A2 (en) * 1994-03-28 1995-10-05 University Of Nottingham Polymer microspheres and a method of production thereof
DE19745950A1 (de) * 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Arzneistoffträgerpartikel für die gewebespezifische Arzneistoffapplikation

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ALYAUTDIN R ET AL: "ANALGESIC ACTIVITY OF THE HEXAPEPTIDE DALARGIN ADSORBED ON THE SURFACE OF POLYSORBATE 80-COATED POLY(BUTYL CYANOACRYLATE) NANOPARTICLES", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 41, no. 1, 1 January 1995 (1995-01-01), pages 44 - 48, XP000482891 *
ALYAUTDIN R N ET AL.: "Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles", PHARMACEUTICAL RESEARCH, vol. 14, no. 3, 1997, pages 325 - 328, XP002102921 *
BLUNK T ET AL.: "Kinetics of plasma protein adsorption on model particles for controlled drug delivery and drug targeting", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 42, no. 4, 1996, pages 262 - 268, XP002102920 *
KREUTER J ET AL: "INFLUENCE OF THE TYPE OF SURFACTANT ON THE ANALGESIC EFFECTS INDUCED BY THE PEPTIDE DALARGIN AFTER ITS DELIVERY ACROSS THE BLOOD-BRAIN BARRIER USING SURFACTANT-COATED NANOPARTICLES", JOURNAL OF CONTROLLED RELEASE, vol. 49, no. 1, 10 November 1997 (1997-11-10), pages 81 - 87, XP000667154 *
KREUTER J: "NANOPARTICLE-BASED DRUG DELIVERY SYSTEMS", JOURNAL OF CONTROLLED RELEASE, vol. 16, no. 1 / 02, 1 June 1991 (1991-06-01), pages 169 - 176, XP000219660 *
LÜCK M ET AL.: "Plasma protein adsorption on biodegradable microspheres consisting of poly(D,L-lactide-co-glycolide), poly(L-lactide) or ABA triblock copolymers containing poly(oxyethylene). Influence of production method and polymer composition", JOURNAL OF CONTROLLED RELEASE, vol. 55, 1998, pages 107 - 120, XP002102924 *
MÜLLER R H ET AL.: "Intravenously injected particles. Surface properties and interaction with blood proteins - the key determining the organ distribution. In: Scientific and Clinical Applications of Magnetic Carriers", 1997, PLENUM PRESS, NEW YORK, XP002102925 *
MÜLLER R H ET AL.: "Solid lipid nanoparticles (SLN) as potential carrier for human use: interaction with human granulocytes", JOURNAL OF CONTROLLED RELEASE, vol. 47, 1997, pages 261 - 269, XP002102923 *
TRÖSTER S D ET AL.: "Modification of the body distribution of poly(methyl methacrylate) nanoparticles in rats by coating with surfactants", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 61, 1990, pages 85 - 100, XP002102922 *

Also Published As

Publication number Publication date
AU2003200687A8 (en) 2003-05-01
DE19745950A1 (de) 1999-04-22
AU1227299A (en) 1999-05-10
EP1023052A2 (de) 2000-08-02
EP1300139A3 (de) 2004-01-28
ATE249209T1 (de) 2003-09-15
US6288040B1 (en) 2001-09-11
DE59809588D1 (de) 2003-10-16
CA2308236A1 (en) 1999-04-29
AU2003200687A1 (en) 2003-05-01
JP2002521311A (ja) 2002-07-16
WO1999020256A2 (de) 1999-04-29
EP1023052B1 (de) 2003-09-10
EP1300139A2 (de) 2003-04-09

Similar Documents

Publication Publication Date Title
WO1999020256A3 (de) Arzneistoffträgerpartikel für die gewebespezifische arzneistoffapplikation
NZ504114A (en) Vitamin k-dependent polypeptides such as protein C where substitution at amino acid sites 11, 12, 29, 33 or 34 affects membrane binding affinity of the protein and ultimately blood clotting ability
NZ236002A (en) Transdermal delivery system for 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazole
EP0374778A3 (de) Verfahren zur Proteinimmobilisierung an einer Festphase, so hergestellte Protein tragende Festphase sowie deren Verwendung
ZA983496B (en) Methods for processing activated protein C.
CY1110884T1 (el) Περιοχη συνδεσης συνδετη (ligand) του rage και χρησεις αυτου
WO2001005950A3 (en) Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
NO302356B1 (no) Pulverformig mannitol med moderat tendens til smuldring, fremstilling av denne mannitol samt preparater inneholdende denne mannitol
FR2766797B1 (fr) Conditionnement pour au moins une matiere solide, notamment sous forme granuleuse ou pulverulente
ZA98533B (en) Soluble CTLA4 mutant molecules and uses thereof.
WO1996009386A3 (en) Allelic variation of the serotonin 5ht2c receptor
WO1997029199A3 (en) Prostate specific antigen peptides and uses thereof
AU7916098A (en) Device for selectively filtering under reduced pressure and for vacuum drying sample liquids or drops of sample liquids as well as use of said device
HK1038756A1 (zh) 人類因子viii及類似因子viii蛋白用的黏合分子
WO2007103788A8 (en) Yeast reporter system based on fusion proteins of sup35p
AUPM769394A0 (en) Assay for the detection of proteases
WO1998050532A3 (en) A process for preparing an anti-oxidant
FR2693246B1 (fr) Disque de frein pour frein à disque de véhicule, en particulier de bicyclette ou similaire.
WO1997026918A3 (en) Ligand directed enzyme prodrug therapy
CA2394746A1 (en) Chromatography material and a method using same
DE3274998D1 (en) Flexible, flat, sand containing laminated article for external use in body treatment
AU9225298A (en) Bifunctional resin composition for the simultaneous separation of carbohydrates and organic acids in liquid chromatography
CA2273272A1 (en) Immediate release drug delivery forms
EP0905480A3 (de) Feststoff-Flüssigkeits-Interdiffusionsverbindung für Ringlaserkreisel
PL319157A1 (en) Pka bonding novel proteins an dtheir application

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2308236

Country of ref document: CA

Ref country code: CA

Ref document number: 2308236

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 12272/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1998955425

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09529600

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998955425

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 1998955425

Country of ref document: EP